Cognitive impairment is common in several neuropsychiatric disorders to a varying degree, including schizophrenia (Sz), bipolar disorder (BD), and major depressive disorder (MDD).
Deficits in core cognitive domains have been consistently shown to strongly predict disability in occupational, social, and community functioning. While some symptoms of major psychiatric disorders are relatively well-controlled by existing treatments, cognitive impairment has been largely unresponsive to standard interventions. The time is ripe for studies that directly target this important domain to promote full recovery.
Cognitive Trial Design in Sz and BD
Over recent years there has been increasing research interest directed toward the treatment of cognitive impairment in Sz 1-3 and BD 4, 5 . While long considered a hallmark symptom of Sz, cognitive deficits have only more recently become recognized as a core feature of BD 6, 7 . Characteristically, cognitive impairment in Sz is known to be diffuse and pervasive, affecting multiple domains and representing a profound negative deviation from normative samples in the order of between 1 and 2 standard deviations or more 8 . Current evidence suggests qualitative similarities in this profile compared with BD, although the magnitude of effects in BD is typically smaller (though not always) [9] [10] [11] [12] . It is well known that cognitive deficits confer a substantial contribution to functioning over and above clinical symptoms in both disorders, and although there is a clear need for novel drug development and novel psychological interventions, currently there remain no pharmacological agents with indications specifically for this symptom dimension.
The MATRICS initiative was introduced over a decade ago to promote the development of pharmacological agents that target neurocognitive impairment in Sz as an independent domain. This was a collaborative effort between the National Institute for Mental health comparators were recommended for adjunctive and broad-spectrum agents respectively, with the trial needing to last long enough to confer enduring effects on cognition of 6 months or longer.
In the context of these recommendations and subsequent advances in the creation of a standardized cognitive test battery for assessing cognitive change in Sz, the International Society of Bipolar Disorders (ISBD) convened a Taskforce to identify a preliminary battery of tests for use in research on BD 13 . From this it was decided that the MCCB could be usefully applied to the disorder, with the addition of more complex measures of verbal learning or executive function as a complement. In combination, these measures form a battery known as the ISBD-battery for the assessment of neurocognition (ISBD-BANC) 14 .
The MCCB tests were subsequently validated in BD 15, 16 and following this, a smaller consensus panel of experts proposed preliminary guidelines for cognitive trial design, drawing on previous efforts in Sz but focusing on the unique nuances of BD 6 . These The existing methodological recommendations for cognitive trial design in both Sz and BD draw on common threads, including the need to recruit clinically stable patients, trial enrichment with patients evidencing meaningful cognitive deficits, the use of a standardized outcome battery for uniform assessment across samples and trials, and the need for secondary or co-primary measures of functioning. Guidance around psychological treatment trial design is still lacking in BD however, and thoughts around this are needed to advance the field.
Cognitive dysfunction in MDD.
As is the case with Sz and BD, cognitive impairment has been increasingly recognized as a core feature of major depressive disorder (MDD), with serious impacts on psychosocial functioning and clinical course 19 . The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study found that nearly 90% of the 2541 patients enrolled reported cognitive difficulties such as problems with concentration and decision making 20 . Patients with MDD experience a broad range of cognitive deficits across domains, including verbal processing, attention, learning, memory, and several aspects of executive functioning including set shifting, working memory, and response inhibition [21] [22] [23] [24] [25] . While the magnitude of cognitive impairments differs by cognitive domain, effect sizes compared to healthy controls appear to be in the medium to large range 26 .
Cognitive deficits are present early in the course of illness, likely by illness onset 27, 28 , and often persist during clinical remission 20, [29] [30] [31] . While some aspects of cognition may be influenced by mood state (e.g. psychomotor speed; memory), others are relatively independent of state mood symptoms (e.g. attention; executive functioning) 27, 30 .
Overall illness severity is associated with cognitive dysfunction in MDD, as has been reported in other affective disorders. Markers of overall illness burden including history of psychosis 29 ; number and total duration of depressive episodes 29, 31 ; severity of depressive symptoms; and melancholic subtype 30 are associated with greater cognitive impairment.
Cognitive deficits are present at similar rates in patients with MDD and other serious mental illnesses such as Sz and BD 32 , and are qualitatively similar, with evidence of impaired underlying attention, verbal learning, and executive functioning across diagnoses 19 . However, the severity of impairment differs quantitatively amongst these disorders, with patients with MDD showing the least severe deficits 25 . In terms of longitudinal course, a cluster analytic approach grouping patients with Sz, BD or MDD based on cognitive change over follow up found no difference in diagnostic makeup of each cluster, suggesting that cognitive trajectories are not diagnosis-specific 28 .
As has been shown for Sz and BD 33, 34 , cognitive impairments are strongly associated with psychosocial functioning across multiple domains in patients with MDD 24, [35] [36] [37] [38] [39] . Not only do cognitive deficits impede community functioning directly, they may also increase rates of recurrent depressive episodes leading to an overall worsening course of illness 23, 24 .
Together these findings demonstrate that cognitive functioning is broadly impaired in patients with MDD, affecting a large majority of patients. Deficits are present early in the course of illness, persist during remission of mood symptoms, and significantly impact community functioning and illness course. Thus, cognitive dysfunction in MDD represents an important target for improving both psychosocial functioning and overall illness trajectory.
Cognitive treatment considerations for MDD.
Many of the same issues arise when considering targeting cognition in MDD as have been These regulatory changes reflect a changing tide in drug development and emphasize the importance of identifying new drug targets that span a broad range of major psychiatric disorders.
Future Directions
The recommendations put forth in this paper are largely focused on the potential use of pharmacological interventions for cognitive trials. The use of psychosocial approaches and cognitive remediation are also of great interest but outside of the scope of this manuscript.
One area of emerging interest that is worth a brief comment here is the growing use of life depression in a small proof-of-concept trial 41 . In addition to achieving cognitive improvements, Project: EVO TM was found to improve mood and self-reported functioning both in older adults and a general adult population with depression 41, 42 . Other app-based interventions for conditions and constructs related to cognition -organization, attentional control, memory, and mindfulness -have also been associated with improvements in mood in samples not specifically recruited for mood disturbance 43, 44 .
Taken together this literature suggests both that digitalized CT can enhance cognition in individuals with depression and that, consistent with findings of overlapping functional neuroanatomy, there is some reciprocity between improvements in depression and cognition.
Additional research could support stronger conclusions. First, more studies on the efficacy of digitalized CT that include active controls and larger sample sizes are necessary. The metaanalysis conducted by Motter et al. 35 only included one study with more than 25 participants.
Second, more support of transferability from findings on in-program tests to improvements on everyday functioning must be evaluated. Finally, teasing out longitudinal relationships between cognitive improvement and mood improvement from digital CT and variables that may impact the direction of this relationship will allow for more precise tailoring of treatment recommendations.
Conclusions.
In response to the clear and convergent evidence that cognitive impairment is among the most disabling of symptoms in major psychiatric illness, several studies are now underway that target cognition directly in patients with Sz and BD. There have been working groups established and expert consensus guidelines published that make recommendations to optimize study design for these disorders. A more recent focus on cognition in MDD points toward the need for similar guidelines tailored to this patient sample and supports the need for intervention trials that focus on this relatively understudied aspect of MDD. Here we set the stage for future work in this arena.
